December 2, 2016
Otsuka Pharmaceutical and its Danish partner Lundbeck said on December 1 that the US FDA has accepted a supplemental new drug application (sNDA) for Abilify Maintena (aripiprazole), a once-monthly injectable version of Abilify, for the additional indication of bipolar I...read more